The inheritance of one defective BRCA1 or BRCA2 allele predisposes an individual to developing breast and ovarian cancers. BRCA1 is a multifunctional tumor suppressor protein, which through interaction with a vast array of proteins has implications in processes such as cell cycle, transcription, DNA damage response and chromatin remodeling. Conversely, the oncogene, cyclin D1 is overexpressed in about 35% of all breast cancer cases. In this study, we provide detailed analyses on the phosphorylation state of BRCA1 by cyclin D1/cdk4 complexes. In particular, we have identified Ser 632 of BRCA1 as a cyclin D1/cdk4 phosphorylation site in vitro. Using chromatin immunoprecipitation assays, we observed that the inhibition of cyclin D1/cdk4 activity resulted in increased BRCA1 DNA binding at particular promoters in vivo. In addition, we identified multiple novel genes that are bound by BRCA1 in vivo. Collectively, these results indicate that cyclin D1/cdk4-mediated phosphorylation of BRCA1 inhibits the ability of BRCA1 to be recruited to particular promoters in vivo. Therefore, cyclin D1/Cdk4 phosphorylation of BRCA1 could provide a mechanism to interfere with the DNA-dependent activities of BRCA1.
Introduction
The inheritance of one defective BRCA1 allele predisposes an individual to developing breast and ovarian cancer (Rosen et al., 2003) . BRCA1 is a tumorsuppressor gene that is critical for genomic stability through facilitating DNA repair, chromatin remodeling, cell-cycle arrest and transcriptional regulation (Boulton, 2006; Rosen et al., 2006) . BRCA1 can act as either a corepressor or a coactivator of transcription by interacting with numerous transcription factors, such as estrogen receptor (ER)-a, p53, STAT1, c-Myc, CtIP and ZBRK1 (Mullan et al., 2006) . Furthermore, the ability of BRCA1 to regulate cell-cycle progression depends on the transcriptional regulation of multiple cell-cycle genes, such as p21/waf1 and p27/kip1 to regulate the G1/S checkpoint, as well as cyclin B1, 14-3-3s, wee1 kinase and GADD45 to influence the G2/M-phase transition (Mullan et al., 2006) . A recent study indicates that BRCA1 can act as a CTD kinase inhibitor contributing to the activation of p21/waf1 gene expression (Moisan and Gaudreau, 2006) , providing another mechanism whereby BRCA1 influences transcription and cell-cycle progression.
Cell-cycle regulatory genes are often targeted in tumorigenesis mainly because this is one way of deregulating and increasing cell proliferation. Cyclin D1 is traditionally viewed as an overexpressed oncogene that increases cellular proliferation through the phosphorylation of the retinoblastoma protein.
The discovery of additional cdk substrates, such as SMAD3 (Matsuura et al., 2004) , in combination with the increasing role of cyclin D1 in transcriptional regulation (Coqueret, 2002) , suggests that cyclin D1/cdk4 phosphorylation events may have additional functions yet to be defined. Likewise, various cyclin/cdk complexes, including cyclin D, have been shown to phosphorylate BRCA1 (Wang et al., 1997; Ruffner et al., 1999) ; however, the consequence of cyclin D1/cdk phosphorylation on BRCA1 has not been determined.
Here, we demonstrate a direct interaction between cyclin D1 and BRCA1 resulting in phosphorylation of BRCA1 at Ser 632. Using chromatin immunoprecipitation (ChIP) assays, we identified multiple novel BRCA1 bound promoters. Our findings indicate that cyclin D1/cdk4 phosphorylation of BRCA1 inhibits the ability of BRCA1 to be recruited to particular promoters in vivo.
Results

Cyclin D1 and BRCA1 interact in breast cancer cells
Initial experiments were designed to confirm that cyclin D1 and BRCA1 physically interact. Our results indicate that the expression of cyclin D1 and BRCA1 is variable between cell lines, with MCF-7 cells expressing higher levels of cyclin D1, and T47D cells expressing higher levels of BRCA1 (Figure 1a, left panel) . Also, a 'normal' breast epithelial cell line, MCF-10A, as well as the breast cancer cell line MDA-MB-231, were examined for both BRCA1 and cyclin D1 expression. Results in Figure 1a (right panel) demonstrate that high levels of BRCA1 protein were present in breast cancer cells and not in normal cells. Using immunoprecipitation assays, we find that cyclin D1 complexes with BRCA1 in MCF-7 and T47D cells (Figures 1b) . In fact, this complex was resistant to 0.6 M NaCl wash conditions, indicative of a very stable complex. Finally, the immunoprecipitates were shown to be specific since in the presence of competing peptide, no pull down of the immune complexes were observed ( Figure 1b, lane 3) . Interestingly, we also observed the presence of ubiquitinated BRCA1 in the cyclin D1 complex based on the presence of multiple high-molecular-weight bands that were further confirmed with anti-ubiquitin antibody (data not shown).
Cyclin D1 and BRCA1 colocalize
To confirm this interaction, we determined whether BRCA1 and cyclin D1 colocalize in the nucleus or cytoplasm. Asynchronous MCF-7 cells, hydroxyurea (HU; early S phase blocker) and nocodazole (G 2 /M blocker)-treated cells were fixed and fluorescently stained for both cyclin D1 and BRCA1 proteins (Figure 2 ). BRCA1 was detected in both the nucleus and cytoplasm of untreated cells, previously reported for MCF-7 cells (Fabbro et al., 2002) . Cyclin D1 staining was also found in both the cytoplasm and nucleus (Figure 2 , untreated cells). However, both cyclin D1 and BRCA1 were present mostly in the nucleus after HU treatment, indicating that they most likely migrate between the cytoplasm and nucleus at various stages of cell cycle. When red and green channels were merged, colocalization could be observed (white arrows). Interestingly, nocodazole-treated cells showed no colocalization of these two complexes (data not shown). These results further confirm that certain population of BRCA1 and cyclin D1 are complexed together in breast cancer cells.
Cyclin D1 and BRCA1 interact through the G 0 /G 1 phase of the cell cycle To determine the cell-cycle-dependent interaction between cyclin D1/BRCA1, MCF-7 cells were analysed at various points in the cell cycle. To obtain cells in different phases of the cell cycle, three different synchronization approaches were utilized (Figure 3a) . G 0 /early G 1 cells were obtained by serum starvation, early S phase cells were collected by treatment with HU, and a G 2 /M-phase cells population was recovered through treatment with nocodazole. Figure 3b demonstrates that an asynchronous MCF-7 population consists of 55.68% G 0 /G 1 cells, 25.88% S phase cells and 18.44% G 2 /M-phase cells. Upon serum starvation, the G 0 /G 1 population could be enriched to 88.62%. MCF-7 cells treated with hydroxyurea, released into complete media and picked up 4 h later, contained 73.63% of the cells in S phase. Cells treated with nocodazole for 24 h were 85.45% at G 2 /M phases.
Next, we performed Western blots on the various cellcycle populations (Figure 3c ). Cyclin D1 was most highly expressed at the early G 1 , and BRCA1 at the early S phase (Figure 3c , lanes 2 and 3, respectively). We next determined if cyclin D1 and BRCA1 complexed at various stages of cell cycle. A prominent complex was observed at the early G 1 and some at the early S phase (panel d). This complex was specific since both BRCA1 and cyclin D1 peptides competed out the antibodies in the immunoprecipitation reaction (panel d).
Cyclin D1 binds and phosphorylates BRCA1 in vitro To narrow down the site of interaction on BRCA1, in vitro binding assays with BRCA1 fusion proteins and 35 S-labeled cyclin D1 were performed. Strong cyclin D1 binding to BRCA1 fragments 1-500 and 504-802 was observed ( Figure 4a , lanes 2 and 4, respectively), but not to regions 1021-1552 (lane 3), 1501-1861 and 697-1276 (data not shown). Average binding results are indicated in Figure 4d . Collectively, these results indicate that regions 1-500 and 504-802 of BRCA1 are important for binding to cyclin D1 in vitro.
BRCA1 is a phospho protein, thus one possible consequence of the BRCA1/cyclin D1 interaction is the phosphorylation of BRCA1. Using in vitro kinase assays, we observed that cyclin D1/cdk complexes phosphorylated GST-BRCA1 fragments including 1-500 and 504-802, but not 697-1276 or 1501-1861 ( Figure 4b ). A stain of various GST-BRCA1-isolated proteins used in panel b is shown in Figure 4c . The binding and phosphorylation profiles of cyclin D1 to various BRCA1 proteins is shown in Figure 4d . Therefore the N terminus (1-500) and the region of (504-802) of BRCA1 appear to be important for the functional interaction between cyclin D1 and BRCA1.
BRCA1 region 630-669 is a preferential target of cyclin D1/cdk4 phosphorylation Cyclin/cdk complexes phosphorylate their substrates through the use of a consensus cdk motif, Ser/Thr followed by Pro (indicated in blue in Figure 5a ), and it is often precluded by a cyclin-binding motif, RXL (indicated in red), and the distance between the cdk and the cyclin binding motif needs to be at least 12 amino acids apart. In regions 1-500 and 504-802 of BRCA1, there are two spans of amino acids that fit the above criteria and peptides spanning these regions are indicated in Figure 5b . Figure 5c demonstrates that BRCA1 630-669 was efficiently phosphorylated by cyclin D1/cdk complexes in vitro, whereas BRCA1 112-141 showed minimal level of phosphorylation (compare lanes 1 and 2). To confirm further the specificity of this phosphorylation, the wild-type BRCA1 peptide was utilized in an in vitro kinase assay, using cyclin D1 immunoprecipitate as well as two other control kinases ( Cyclin D1/cdk4 phosphorylates BRCA1 in vivo To demonstrate that cyclin D1/cdk4 complexes phosphorylate BRCA1 in vivo, a cdk4 inhibitor, Fascaplysin, was utilized (Soni et al., 2000) . It has been demonstrated in vitro to have an IC 50 of 0.35 mM against cyclin D1/cdk4. Asynchronous MCF-7 cells were treated for 24 h with various concentrations of Fascaplysin (0.50, 0.75, 1 and 1.25 mM). Significant inhibition of BRCA1 phosphorylation was observed with as little as 0.75 mM Fascaplysin (Figure 6a, lane 3) . Also, the addition of exogenous PP2A into dimethylsulfoxide (DMSO)-treated cell extracts showed a B50% drop in the phosphorylated form of BRCA1 (Figure 6b ), further indicating the presence of phosphorylated BRCA1 in MCF-7 cells.
To confirm further the role of cdk4 in BRCA1 phosphorylation, we used siRNA against cdk4 and cdk9 as a control followed by Western blotting (Figure 6c ). In cells transfected with cdk4 siRNA, we observed low levels of phosphorylated BRCA1 and a total decrease in BRCA1 levels, whereas in cells transfected with cdk9 siRNA, we saw no change in the level of BRCA1 phosphorylation. A Western blot of siRNA-treated cell extracts is shown in panel d. A comparison of panels a and c reveals that Fascaplysin may inhibit the activity of cdk4 towards the phosphorylation of BRCA1 at the Ser 632 residue, and not other serine residues. On the other hand, cdk4 degradation by siRNA may result in loss of BRCA1 phosphorylation on other serine sites, leading to dephosphorylation and possible degradation. Immune complexes were used for in vitro kinase assays using peptides shown in (b). (d) MCF-7 cell extracts (1 mg) were IPed with anti-cyclin D1, anti-cyclin A, anti-cyclin G antibodies. Immune complexes were used for in vitro kinase assays using the BRCA1 630-669 WT peptide and mutant (S632A) peptide. Kinase reactions were separated, stained, destained, dried and exposed to a PhosphorImager cassette. For inhibition studies, 1 mM of Fascaplysin was used. (e) Similar kinase reactions were performed as in (d), utilizing either BRCA1 630-669 WT peptide, BRCA1 630-669 scrambled peptide (Scr; LSPP site has been changed to PSPL, and the SRNL has been changed to LSNR) or Rb-B peptide (de La Fuente et al., 2000) as substrates.
been experimentally tested to interact with BRCA1. Therefore, ChIP experiments were designed to determine if BRCA1 binds to these genes in vivo. Upon design of the primers to be used for polymerase chain reaction (PCR), only 14 out of the 23 genes could be confirmed to contain the BRCA1 DNA consensusbinding site. The pS2 gene was utilized as a positive control (Zheng et al., 2001) , and FEN1 and ORC4L were used as negative controls. Out of the 15 genes tested for the presence of BRCA1, nine were positive (Figure 7a ). These included RING1 and YY1 bindingprotein (RYBP), Ras homologue gene family member G, RhoG (ARHG), APEX nuclease (APEX), somatostatin (SST), estrogen receptor 2, ERb (ESR2), 2 0 -5 0 -oligoadenylate synthetase 1 (OAS1) and estrogenregulated gene (pS2). Importantly, none of these genes, except for our positive control, pS2, has previously been shown to be bound by BRCA1 in vivo.
Experiments were then designed to examine the effects of cyclin D1/cdk4 phosphorylation on BRCA1 DNA binding. After treatment of MCF-7 cells with Fascaplysin, increased BRCA1 binding to SST and FHX was observed using ChIP assays (Figure 7b) . Finally, when utilizing siRNA against cdk4, BRCA1 binding was increased at both the SST and FHX promoters, but not in the presence of cdk2 siRNA (Figure 7c ).
Discussion
Previous studies have shown that the first 76 aa of BRCA1 interact with multiple cell-cycle factors including cdc2, cdk2, cdk4, cyclin B, cyclin D, cyclin A and E2F-4 (Wang et al., 1997) . Our data demonstrates that the principal areas of interaction are the N terminus (aa 1-500) and aa 504-802. Furthermore, BRCA1 is targeted for phosphorylation by numerous cell-cycle kinases including cyclin A/cdk2, cyclin E/cdk2 and cyclin D1/cdk4 (Chen et al., 1996; Ruffner et al., 1999) . BRCA1, through its tumor suppressor function, acts to protect cells from unwanted excessive growth. The opposing roles of BRCA1 and cyclin D1 in cell-cycle progression and tumorigenesis, and our results presented within indicate that cyclin D1 phosphorylation of BRCA1 results in the inhibition of BRCA1. Importantly, we demonstrated that the use of a cdk4 specific drug, Fascaplysin, resulted in decreased BRCA1 phosphorylation in vivo. There has long been a search for cdk4 inhibitors and more potent derivatives of Fascaplysin are currently being developed (Aubry et al., 2004) . In addition, cdk inhibitors have been potentially useful chemotherapeutic agents that have progressed into phase III clinical trials. Therefore, it is reasonable to believe that Fascaplysin could be a useful tool to restore the cell's natural protection (i.e. unphosphorylated BRCA1) in sporadic breast cancers where cyclin D1 is overexpressed.
During the preparation of this manuscript, cyclin D1 was shown to compete with BRCA1 for binding to ER (Wang et al., 2005) . This work demonstrated that BRCA1 and cyclin D1 formed two separate complexes with ER that through competition allows differential regulation of estrogen-responsive genes. The promoter of the estrogen-responsive gene, pS2, was found to be occupied by BRCA1, but when cyclin D1 was overexpressed, this association was decreased. Furthermore, this competition was independent of cdk activity. Our current study does not conflict with these results, but rather demonstrates a separate function of cyclin D1 that is phosphorylation dependent. In fact, we also observed BRCA1 on the pS2 promoter and found no difference in the levels of BRCA1 after treatment with Fascaplysin, indicating that cyclin D1/cdk4 kinase activity did not affect the binding of BRCA1 to the pS2 promoter. However, we have found multiple novel BRCA1 bound promoters (RYBP, ARHG, APEX, SST, ESR2, OAS1 and FHX) containing the previously described BRCA1 DNA consensus sequence (TTC(G/ T)GTTG ) as well as two BRCA1 bound promoters (SST and FHX) that have reduced BRCA1 binding in the presence of a cdk4 inhibitor. SST is a peptide hormone that exerts antisecretory and antiproliferative activities through the inhibition of growth hormones (Hejna et al., 2002) . Interestingly, SST has been shown to be regulated by CAMP response element-binding protein (CREB) and CBP (Montminy et al., 1996) , whereas BRCA1 has been shown to either activate or inhibit genes by binding to CBP (Pao et al., 2000; Fan et al., 2002) . On the basis of these previous studies, we speculate that the presence of BRCA1 at the SST promoter helps induce its transcription to ultimately positively contribute to the cell-cycle checkpoint activity of BRCA1. Importantly, in the presence of a cyclin D1/cdk inhibitor, we observed increased BRCA1 association at the SST promoter, indicating that phosphorylation of BRCA1 by cyclin D1/cdk4 results in decreased BRCA1 binding to the SST promoter. A model of how this may occur is depicted in Figure 8 .
The second promoter that exhibited differential BRCA1 occupation after cyclin D1/cdk4 inhibition was the FOXJ2 Foxhead transcription factor (FHX). FOXJ2 is a member of the Forkhead-box (FOX) gene family, which consists of at least 43 members (Katoh and Katoh, 2004) . FOXJ2 is further classified as a class I family member, which contains a C-terminal basic region within their FOX domain. Although very little is known about FOXJ2, another class I member, FOXA1, is amplified and overexpressed in esophageal and lung cancer (Lin et al., 2002) . Other FOX family members are implicated in basal cell carcinomas, pancreatic cancer and secondary acute myeloblastic leukemia (Hillion et al., 1997; Nakamura et al., 2004; Teh et al., 2002) . The role of BRCA1 at this promoter is unknown and has not been demonstrated here. However, based on the implication of FOXJ2 in the oncogenic process, it can be speculated that BRCA1 might aid in suppressing FHX transcription.
Collectively, five of the genes that were observed with BRCA1 present are implicated in or have functions related to tumor suppression or antiproliferation including, RYBP, APEX, SST, OAS1 and possibly ESR2. The remaining two genes ARHG and FHX appear to be involved in positively regulating the progression of the Cyclin D1 phosphorylates BRCA1 K Kehn et al cell cycle or aiding in tumorigenesis. Therefore, we speculate that BRCA1 binds the promoters of these five genes to enhance their transcription, whereas it is present at the ARHG and FHX promoters to inhibit transcription. This dual role of BRCA1 is well documented in the literature, with the activation of p21/waf1 and the inhibition of ERa being prime examples. Our future studies will experimentally test this hypothesis.
Materials and methods
Cell culture MCF-7, T47D and MDA-MB-231 are breast cancer epithelial cells derived from pleural effusions (Lacroix and Leclercq, 2004) . MCF-10A is a normal breast epithelial cell line. T47D cells were grown in RPMI 1640 containing 10% fetal bovine serum (FBS), 1% L-glutamine and 1% streptomycin/penicillin. MCF-7 and MDA-MB-231 cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% FBS, 1% L-glutamine, and 1% streptomycin/penicillin. MCF-10A cells were grown in mammary epithelial cell medium plus 100 ng/ml of cholera toxin. All cells were maintained in a 5% CO 2 incubator at 371C. Plasmids pDC78 GST-BRCA1 (1-500), pDC79 GST-BRCA1 (452-1079), pDC80 GST-BRCA1 (1021-1552), pDC81 GST-BRCA1 (1501-1861), pDC99 GST-BRCA1 (504-802), pDC208 GST-BRCA1 (697-1276) were a kind gift from Dr Tanya Paull at the University of Texas/ICMB, which were originally made in Dr Elledge's lab at Vanderbilt University (Cortez et al., 1999) .
Antibodies, immunoblotting, kinase and ChIP assays Whole-cell lysates and immunoblotting have previously been described (Santiago et al., 1999) . Anti-cyclin D1 (M-20) and anti-BRCA1 (C-20) polyclonal antibodies were purchased from Santa Cruz (CA, USA). Human protein phosphatase PP2A was purchased from Upstate Biotechnology (Lake Placid, NY, USA). The membranes were probed with a 1:200 dilution of primary antibodies overnight at 41C, followed by washes in PBS þ 0.1% Tween-20. The blots were then probed with a 1:750 dilution of secondary antibodies for 1 h at 41C, followed by washes in PBS þ 0.1% Tween-20 and detected using a SuperSignal West Dura Extended Duration Substrate Kit (Pierce, Rockford, IL, USA). Cyclin D1 and actin were detected with 125 I-Protein G; BRCA1 was detected by ECL. Kinase assays were performed as previously described (Kehn et al., 2004) . ChIP assays were performed as described previously (Kehn et al., 2004) . Transcription complexes were immunoprecipitated with 5 mg antibodies including Tab 172 (control), anti-BRCA1 (C-20) rabbit polyclonal (C-20, Santa Cruz), anti IgG, and anti-phosphorylated Ser 10 histone H3 mouse monoclonal (#05-598, Upstate). Thirty-five cycles of PCR were performed and products were separated by electrophoresis on 2% agarose gels and visualized by ethidium bromide staining.
Immunofluorescent staining and confocal laser scanning microscopy Immunofluorescent staining was performed as described previously (Kehn et al., 2004) with the following exceptions. A mouse monoclonal anti-BRCA1 (Oncogene Research Products, Cambridge, MA, USA; Ab-1; 1:50) and rabbit polyclonal anti-cyclin D1 (Santa Cruz; M-20; 1:200) were used as primary antibodies. Secondary antibodies used were AlexaFluora 488-goat anti-rabbit immunoglobulin G (IgG) (1:200) and AlexaFluora 568-goat anti-mouse IgG (Molecular Probes, Carlsbad, CA, USA; 1:50). The immune complexes were washed twice with 0.6 M NaCl þ 0.1% NP-40 and once with PBS. The immunoprecipitates were shown to be specific, since in the presence of competing peptide, no pull down of the immune complexes were observed (Figure 1b, lane 3) .
Slides were viewed with a Bio-Rad MRC1024 confocal laser-scanning microscope (Hercules, CA, USA) using the Â 60 objective. Triple excitation at 488, 568 and 647 nm was used. Optical sections were taken using z-dimensions between 0.5 and 1.0 mm. Cyclin D1 phosphorylates BRCA1 K Kehn et al
